This article is a correction to:
Discovery of spirooxindole-derived small-molecule compounds as novel HDAC/MDM2 dual inhibitors and investigation of their anticancer activity
Qian Zhao1†
Shan-Shan Xiong
Xin Xie
Gu He
Bo Han- 1State Key Laboratory of Southwestern Chinese Medicine Resources, Hospital of Chengdu University of Traditional Chinese Medicine, School of Basic Medical Sciences, Chengdu University of Traditional Chinese Medicine, Chengdu, China
- 2Department of Dermatology and State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, China
- 3School of Pharmacy, Chengdu Medical College, Chengdu, China
- 4The First Affiliated Hospital, Chengdu Medical College, Chengdu, China
- 5Antibiotics Research and Re-evaluation Key Laboratory of Sichuan Province, Sichuan Industrial Institute of Antibiotics, Chengdu University, Chengdu, China
A corrigendum on
Discovery of spirooxindole-derived small-molecule compounds as novel HDAC/MDM2 dual inhibitors and investigation of their anticancer activity
by Zhao Q, Xiong S-S, Chen C, Zhu H-P, Xie X, Peng C, He G and Han B (2022). Front. Oncol. 12:972372. doi: 10.3389/fonc.2022.972372
In the published article, there was an error in Table 1 (Effects of substituted group R1 and R2 on enzyme inhibition) as published. The figures A-C insert in Table 1 were found to be incorrect. The corrected Table 1 and its caption appear below.
TABLE 1
Table 1 Effects of substituted group R1 and R2 on enzyme inhibition.
In addition, there was an error in Table 2 (Effects of amino acids 3 on enzyme inhibition) as published. The figures A-C insert in Table 2 were found to be incorrect. The corrected Table 2 and its caption appear below.
TABLE 2
Table 2 Effects of amino acids 3 on enzyme inhibition.
The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Keywords: multitarget drugs, histone deacetylase inhibitors, MDM2 inhibitors, spirooxindole, dual inhibitors, anticancer
Citation: Zhao Q, Xiong S-S, Chen C, Zhu H-P, Xie X, Peng C, He G and Han B (2023) Corrigendum: Discovery of spirooxindole-derived small-molecule compounds as novel HDAC/MDM2 dual inhibitors and investigation of their anticancer activity. Front. Oncol. 13:1259550. doi: 10.3389/fonc.2023.1259550
Received: 16 July 2023; Accepted: 24 July 2023;
Published: 25 August 2023.
Edited and Reviewed by:
Leilei Fu, Southwest Jiaotong University, ChinaCopyright © 2023 Zhao, Xiong, Chen, Zhu, Xie, Peng, He and Han. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Cheng Peng, pengcheng@cdutcm.edu.cn; Gu He, hegu@scu.edu.cn; Bo Han, hanbo@cdutcm.edu.cn
†These authors have contributed equally to this work